Taken together, these findings suggest a therapeutic intervention with PI3K pathway inhibitors, such as mTOR (mammalian target of rapamycin) inhibitors, for the treatment of HHT [12,14]. This evidence concerns the gene MTOR and hereditary hemorrhagic telangiectasia.